Detalles de la búsqueda
1.
Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol
; 129(5): 618-626.e2, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35926824
2.
Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.
Ann Allergy Asthma Immunol
; 122(6): 630-638.e3, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30910440
3.
Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis.
Allergy Asthma Proc
; 40(4): 261-272, 2019 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31053180
4.
Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis.
Allergy Asthma Proc
; 40(5): 301-310, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31248471
5.
The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
J Asthma
; 55(8): 898-906, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28933971
6.
Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
J Asthma
; 55(6): 640-650, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28763243
7.
A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma.
Allergy Asthma Proc
; 38(4): 264-276, 2017 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28540844
8.
Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
Allergy Asthma Proc
; 38(5): 343-353, 2017 09 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28639542
9.
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.
Eur Respir J
; 44(5): 1156-65, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25234803
10.
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
Respir Res
; 15: 123, 2014 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25756831
11.
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
BMC Pulm Med
; 14: 178, 2014 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25404569
12.
Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial.
BMC Pulm Med
; 14: 209, 2014 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25539654
13.
Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
COPD
; 10(4): 511-22, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23819698
14.
One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.
COPD
; 10(4): 500-10, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23679347
15.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Eur Respir J
; 40(4): 830-6, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22441743
16.
Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹4C]-aclidinium bromide in healthy subjects.
Biopharm Drug Dispos
; 33(1): 39-45, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22275272
17.
Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
COPD
; 9(2): 90-101, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22320148
18.
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Respir Res
; 12: 55, 2011 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-21518460
19.
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Int J Infect Dis
; 103: 62-71, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33212256
20.
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Int J Infect Dis
; 105: 686-687, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33601032